Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study

Francesco Deodato, Gian Carlo Mattiucci, Vincenzo Valentini, Alessio Giuseppe Morganti, Mariangela Massaccesi, Luciana Caravatta, Gabriella Macchia, Vincenzo Picardi, Edy Ippolito, Samantha Mignogna, Milena Ferro, Savino Cilla

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).
Lingua originaleEnglish
pagine (da-a)4585-4589
Numero di pagine5
RivistaAnticancer Research
Volume33
Stato di pubblicazionePubblicato - 2013

Keywords

  • Adenocarcinoma
  • Administration, Metronomic
  • Aged
  • Aged, 80 and over
  • Chemoradiation
  • Chemoradiotherapy
  • Disease-Free Survival
  • Dose Fractionation
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Prospective Studies
  • Prostatic Neoplasms, Castration-Resistant
  • Treatment Outcome
  • hormone-refractory prostate cancer
  • metronomic chemotherapy
  • phase I study

Fingerprint

Entra nei temi di ricerca di 'Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study'. Insieme formano una fingerprint unica.

Cita questo